Previous Close | 25.15 |
Open | 25.85 |
Bid | 21.58 x 1200 |
Ask | 36.45 x 800 |
Day's Range | 24.25 - 26.26 |
52 Week Range | 21.25 - 96.88 |
Volume | |
Avg. Volume | 818,893 |
Market Cap | 1.376B |
Beta (5Y Monthly) | 0.79 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.95 |
Earnings Date | Jul 27, 2022 - Aug 01, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 60.29 |
Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant OutcomesSOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the International Society for Heart and Lung Transplantation (ISHLT) has selected Dr. Berta Sáez-Gimé
Natera Recycles Old IP for New Lawsuits SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Natera has just dropped one of their two patents originally asserted against CareDx. At the same time, Natera asserted two patents that are variations of the o
Posters and Symposium Feature Latest Advances in AlloSeq Portfolio Including HLA Typing and Hematopoietic Stem Cell and Organ Transplant MonitoringSOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will be presenting the latest information on its AlloS